Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Phys Rev Lett ; 132(10): 101003, 2024 Mar 08.
Article in English | MEDLINE | ID: mdl-38518339

ABSTRACT

We use multimessenger observations of the neutron star merger event GW170817 to derive new constraints on axionlike particles (ALPs) coupling to photons. ALPs are produced via Primakoff and photon coalescence processes in the merger, escape the remnant, and decay back into two photons, giving rise to a photon signal approximately along the line of sight to the merger. We analyze the spectral and temporal information of the ALP-induced photon signal and use the Fermi Large Area Telescope (Fermi-LAT) observations of GW170817 to derive our new ALP constraints. We also show the improved prospects with future MeV γ-ray missions, taking the spectral and temporal coverage of Fermi-LAT as an example.

2.
Influenza Other Respir Viruses ; 5(4): 225-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21651732

ABSTRACT

OBJECTIVES: To describe the association of Aspergillus with influenza. DESIGN/SETTING/SAMPLE: Three case reports of ICU patients with influenza complicated by the isolation of Aspergillus species are described and a review of the literature on the topic was performed. CONCLUSIONS: Severe influenza cases can be complicated by Aspergillus infection.


Subject(s)
Aspergillosis/diagnosis , Aspergillus/isolation & purification , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/complications , Influenza, Human/pathology , Aspergillosis/microbiology , Aspergillosis/pathology , Bronchoscopy , Critical Illness , Female , Humans , Influenza, Human/virology , Intensive Care Units , Male , Middle Aged , Radiography, Thoracic , Severity of Illness Index , Tomography, X-Ray Computed
3.
Clin Ther ; 26(1): 15-28, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14996514

ABSTRACT

BACKGROUND: Osteoporosis and fragility fractures in men account for substantial health care expenditures and decreased quality of life. OBJECTIVE: This article reviews the most current information about the epidemiology, diagnosis, prevention, and treatment of osteoporosis in men. METHODS: Relevant literature was identified through a search of MEDLINE (1966-June 2003) limited to English-language studies in men. The search terms included fractures, bone density, or osteoporosis plus either epidemiology, diagnosis, prevention, control, or therapy. Additional search terms included specific subtopics (eg, bisphosphonates, calcium, exercise, parathyroid hormone). The authors contributed additional relevant publications. RESULTS: Morbidity after fragility fracture is at least as high in men as in women, and the rate of fracture-related mortality 1 year hip fracture is approximately double in men compared with women. The bioavailable fraction of testosterone slowly declines into the ninth decade in men. There is evidence that the effect of estrogen on bone is greater than that of testosterone in men. Diagnosing osteoporosis in men is complicated by a lack of consensus on how it should be defined. Significant risk factors for osteoporosis or fracture include low bone mineral density, previous fragility fracture, maternal history of fracture, marked hypogonadism, smoking, heavy alcohol intake or alcoholism, low calcium intake, low body mass or body mass index, low physical activity, use of bone-resorbing medication such as glucocorticoids, and the presence of such conditions as hyperthyroidism, hyperparathyroidism, and hypercalciuria. Prevention is paramount and should begin in childhood. During adulthood, calcium (1000-1500 mg/d), vitamin D (400-800 IU/d), and adequate physical activity play crucial preventive roles. When treatment is indicated, the bisphosphonates are the first choice, whereas there is less support for the use of calcitonin or androgen therapy. Parathyroid hormone (1-34) is a promising anabolic therapy. There is also strong evidence for the use of bisphosphonates for the treatment of glucocorticoid-induced osteoporosis.


Subject(s)
Osteoporosis , Androgens/therapeutic use , Bone Density , Calcitonin/therapeutic use , Calcium/therapeutic use , Diphosphonates/therapeutic use , Fluorides/therapeutic use , Humans , Life Style , Male , Osteoporosis/epidemiology , Osteoporosis/prevention & control , Osteoporosis/therapy , Parathyroid Hormone/therapeutic use , Risk Factors , Vitamin D/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...